SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Pfizer Inc.

SG&A Trends: Eli Lilly vs. Pfizer Over a Decade

__timestampEli Lilly and CompanyPfizer Inc.
Wednesday, January 1, 2014662080000014097000000
Thursday, January 1, 2015653300000014809000000
Friday, January 1, 2016645200000014837000000
Sunday, January 1, 2017658810000014784000000
Monday, January 1, 2018597510000014455000000
Tuesday, January 1, 2019621380000014350000000
Wednesday, January 1, 2020612120000011615000000
Friday, January 1, 2021643160000012703000000
Saturday, January 1, 2022644040000013677000000
Sunday, January 1, 2023694120000014771000000
Monday, January 1, 2024859380000014730000000
Loading chart...

Cracking the code

SG&A Efficiency: A Decade of Insights

In the ever-evolving pharmaceutical industry, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Over the past decade, Eli Lilly and Company and Pfizer Inc. have demonstrated distinct strategies in managing these costs. From 2014 to 2023, Pfizer consistently allocated more than double the SG&A expenses compared to Eli Lilly, peaking at approximately $14.8 billion in 2016. Meanwhile, Eli Lilly maintained a more conservative approach, with expenses hovering around $6.4 billion, except for a notable dip in 2018. This strategic difference highlights Pfizer's aggressive market expansion and Eli Lilly's focus on streamlined operations. As of 2023, both companies show a trend of increasing SG&A expenses, reflecting the industry's response to global challenges and opportunities. These insights offer a window into the financial strategies shaping the future of pharmaceuticals.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025